Literature DB >> 15538631

Characterization of six novel mutations in the CYBB gene leading to different sub-types of X-linked chronic granulomatous disease.

Marie José Stasia1, Pierre Bordigoni, Daniel Floret, Jean Paul Brion, Cécile Bost-Bru, Gérard Michel, Pierre Gatel, Denis Durant-Vital, Marie Antoinette Voelckel, Xing Jun Li, Michèle Guillot, Elisabeth Maquet, Cécile Martel, Françoise Morel.   

Abstract

Chronic granulomatous disease is an inherited disorder in which phagocytes lack a functional NADPH oxidase and so cannot generate superoxide anions (O(2) (-)). The most common form is caused by mutations in CYBB encoding gp91 phox, the heavy chain of flavocytochrome b(558) (XCGD). We investigated 11 male patients and their families suspected of suffering from X-linked CGD. These XCGD patients were classified as having different variants (X91(0), X91(-) or X91(+)) according to their cytochrome b(558) expression and NADPH oxidase activity. Nine patients had X91(0) CGD, one had X91(-) CGD and one had X91(+) CGD. Six mutations in CYBB were novel. Of the four new X91(0) CGD cases, three were point mutations: G65A in exon 2, G387T in exon 5 and G970T in exon 9, leading to premature stop codons at positions Try18, Try125 and Glu320, respectively, in gp91 phox. One case of X91(0) CGD originated from a new 1005G deletion detected in exon 9. Surprisingly, four nonsense mutations in exon 5 led to the generation of two mRNAs, one with a normal size containing the mutation and the other in which exon 5 had been spliced. A novel X91(-) CGD case with low gp91 phox expression was diagnosed. It was caused by an 11-bp deletion in the linking region between exon 12 and intron 12, activating a new cryptic site. Finally, a new X91(+) CGD case was detected, characterized by a missense mutation Leu505Arg in the potential NADPH-binding site of gp91 phox. No clear correlation between the severity of the clinical symptoms and the sub-type of XCGD could be established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538631     DOI: 10.1007/s00439-004-1208-5

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  40 in total

Review 1.  The association of nonsense codons with exon skipping.

Authors:  C R Valentine
Journal:  Mutat Res       Date:  1998-09       Impact factor: 2.433

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Polymorphic DNA region adjacent to the 5' end of the human insulin gene.

Authors:  G I Bell; J H Karam; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

4.  Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488-497 gp91(phox) deletion mutant.

Authors:  L Yu; A R Cross; L Zhen; M C Dinauer
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  Molecular and functional characterization of a new X-linked chronic granulomatous disease variant (X91+) case with a double missense mutation in the cytosolic gp91phox C-terminal tail.

Authors:  Marie José Stasia; Bernard Lardy; Andres Maturana; Pascale Rousseau; Cécile Martel; Pierre Bordigoni; Nicolas Demaurex; Françoise Morel
Journal:  Biochim Biophys Acta       Date:  2002-04-24

6.  The respiratory burst of bovine neutrophils. Role of a b type cytochrome and coenzyme specificity.

Authors:  F Morel; J Doussiere; M J Stasia; P V Vignais
Journal:  Eur J Biochem       Date:  1985-11-04

7.  Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells.

Authors:  Clara Bionda; Xing Jun Li; Robin van Bruggen; Michel Eppink; Dirk Roos; Françoise Morel; Marie-José Stasia
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

8.  Mutations in the promoter region of the gene for gp91-phox in X-linked chronic granulomatous disease with decreased expression of cytochrome b558.

Authors:  P E Newburger; D G Skalnik; P J Hopkins; E A Eklund; J T Curnutte
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes.

Authors:  A W Segal; I West; F Wientjes; J H Nugent; A J Chavan; B Haley; R C Garcia; H Rosen; G Scrace
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

10.  Molecular analysis in three cases of X91- variant chronic granulomatous disease.

Authors:  H N Bu-Ghanim; A W Segal; N H Keep; C M Casimir
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

View more
  8 in total

Review 1.  Hematologically important mutations: X-linked chronic granulomatous disease (third update).

Authors:  Dirk Roos; Douglas B Kuhns; Anne Maddalena; Joachim Roesler; Juan Alvaro Lopez; Tadashi Ariga; Tadej Avcin; Martin de Boer; Jacinta Bustamante; Antonio Condino-Neto; Gigliola Di Matteo; Jianxin He; Harry R Hill; Steven M Holland; Caroline Kannengiesser; M Yavuz Köker; Irina Kondratenko; Karin van Leeuwen; Harry L Malech; László Marodi; Hiroyuki Nunoi; Marie-José Stasia; Anna Maria Ventura; Carl T Witwer; Baruch Wolach; John I Gallin
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

2.  Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort.

Authors:  Bijun Sun; Zeyu Zhu; Xiaoying Hui; Jinqiao Sun; Wenjie Wang; Wenjing Ying; Qinhua Zhou; Haili Yao; Jia Hou; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2022-07-07       Impact factor: 8.317

3.  Clinical, functional and genetic analysis of twenty-four patients with chronic granulomatous disease - identification of eight novel mutations in CYBB and NCF2 genes.

Authors:  Cécile Martel; Michelle Mollin; Sylvain Beaumel; Jean Paul Brion; Charles Coutton; Véronique Satre; Gaëlle Vieville; Mary Callanan; Christine Lefebvre; Alexandra Salmon; Anne Pagnier; Dominique Plantaz; Cécile Bost-Bru; Laurence Eitenschenck; Isabelle Durieu; Daniel Floret; Claire Galambrun; Hervé Chambost; Gérard Michel; Jean-Louis Stephan; Olivier Hermine; Stéphane Blanche; Nathalie Blot; Hervé Rubié; Guillaume Pouessel; Stephanie Drillon-Haus; Bernard Conrad; Klara M Posfay-Barbe; Zuzana Havlicekova; Tamara Voskresenky-Baricic; Kelecic Jadranka; Maria Cristina Arriazu; Luis Alberto Garcia; Lamia Sfaihi; Lamia Sfaihi Ben Mansour; Pierre Bordigoni; Marie José Stasia
Journal:  J Clin Immunol       Date:  2012-05-05       Impact factor: 8.317

4.  Heterozygote Advantage of the rs3794624 Polymorphism in CYBA for Resistance to Tuberculosis in Two Chinese Populations.

Authors:  Qianqian Liu; Shouquan Wu; Miao Xue; Andrew J Sandford; Jingcan Wu; Yu Wang; Guo Chen; Chuanmin Tao; Yin Tang; Yulin Feng; Jun Luo; Jian-Qing He
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

5.  Inherent X-Linked Genetic Variability and Cellular Mosaicism Unique to Females Contribute to Sex-Related Differences in the Innate Immune Response.

Authors:  Zoltan Spolarics; Geber Peña; Yong Qin; Robert J Donnelly; David H Livingston
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

Review 6.  Genetics and immunopathology of chronic granulomatous disease.

Authors:  Marie José Stasia; Xing Jun Li
Journal:  Semin Immunopathol       Date:  2008-05-29       Impact factor: 11.759

7.  A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma.

Authors:  Setareh Mamishi; Kamiar Zomorodian; Farshid Saadat; Mohsen Gerami-Shoar; Bita Tarazooie; Seyad Ahmad Siadati
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-03-03       Impact factor: 3.944

8.  Very Early-Onset Inflammatory Manifestations of X-Linked Chronic Granulomatous Disease.

Authors:  Roxane Labrosse; Jane Abou-Diab; Annaliesse Blincoe; Guilhem Cros; Thuy Mai Luu; Colette Deslandres; Martha Dirks; Laura Fazilleau; Philippe Ovetchkine; Pierre Teira; Françoise LeDeist; Isabel Fernandez; Fabien Touzot; Helene Decaluwe; Ugur Halac; Elie Haddad
Journal:  Front Immunol       Date:  2017-09-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.